Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP456349.RARQLpEtJmFWLRo8wQ2PJJv50ZmamQS8v1McwpPe8E32M130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456349.RARQLpEtJmFWLRo8wQ2PJJv50ZmamQS8v1McwpPe8E32M130_provenance.
• NP456350.RASFJBb97sxftSRWGJOEYbN4OZVtWTBBuyzv9F-pesR7U130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456350.RASFJBb97sxftSRWGJOEYbN4OZVtWTBBuyzv9F-pesR7U130_provenance.
• NP456352.RAV_O3ronp7ILQVCkzADggUv3Pr5pwuJzCfZY-Q6jeSiY130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456352.RAV_O3ronp7ILQVCkzADggUv3Pr5pwuJzCfZY-Q6jeSiY130_provenance.
• NP456359.RAZ71DNXmMzNGMEAQ5BFtZGd6PdjNORU2npldcsvahKk0130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456359.RAZ71DNXmMzNGMEAQ5BFtZGd6PdjNORU2npldcsvahKk0130_provenance.
• NP456361.RAafIJQkORZKlUuMaWbp-_RlwRXfzporV2LPvDCMX_8Ww130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456361.RAafIJQkORZKlUuMaWbp-_RlwRXfzporV2LPvDCMX_8Ww130_provenance.
• NP456362.RAf4ve8NQml9_xAOLODgyryQhNZRoD9PPp6CWUqo4L3_o130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456362.RAf4ve8NQml9_xAOLODgyryQhNZRoD9PPp6CWUqo4L3_o130_provenance.
• NP456367.RAUd9dV3aiTz7IRADbF4AQWu9K340qEgNsiTE4dENaxGM130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456367.RAUd9dV3aiTz7IRADbF4AQWu9K340qEgNsiTE4dENaxGM130_provenance.
• NP456369.RAaaBOFeBYobiUJstUIllJGaZinVpACMzd_jEP1lzigN4130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456369.RAaaBOFeBYobiUJstUIllJGaZinVpACMzd_jEP1lzigN4130_provenance.
• NP456365.RADFX2EFohd07DOscITjlne2gqVGKFtJR-RnV2HAbmv_0130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456365.RADFX2EFohd07DOscITjlne2gqVGKFtJR-RnV2HAbmv_0130_provenance.
• NP456351.RAjpAU5-0ApD5AmB13H2Bjchb_vGfy6cxfCANOHiqes2g130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456351.RAjpAU5-0ApD5AmB13H2Bjchb_vGfy6cxfCANOHiqes2g130_provenance.
• NP456354.RAtBrUUtLEcIhkJ0OSZBq8EhUUlE2wzZ9dd0QCN5pC1cw130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456354.RAtBrUUtLEcIhkJ0OSZBq8EhUUlE2wzZ9dd0QCN5pC1cw130_provenance.
• NP456356.RAhQDJUnPn50DsyTCaa8GMUx8_xUQURf5z4DQsMULMILo130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456356.RAhQDJUnPn50DsyTCaa8GMUx8_xUQURf5z4DQsMULMILo130_provenance.
• NP456363.RAp845bZELO5H3oYx9BpfQiqPBHVFfBRqFt0V5e9v9Ei0130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456363.RAp845bZELO5H3oYx9BpfQiqPBHVFfBRqFt0V5e9v9Ei0130_provenance.
• NP456355.RAJ4BqF15cOmzmcMqVwIPOP_Z36L59UFpKkrZhebCxz2I130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456355.RAJ4BqF15cOmzmcMqVwIPOP_Z36L59UFpKkrZhebCxz2I130_provenance.
• NP456357.RAEljv4T64ybyQzeiBdsY04-VAd4UhJyn4hUvRqULir1Q130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456357.RAEljv4T64ybyQzeiBdsY04-VAd4UhJyn4hUvRqULir1Q130_provenance.
• NP456353.RAxVrp8EVBpXr3Rf3exjEKpcezy386ynloittzhZOuIi4130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456353.RAxVrp8EVBpXr3Rf3exjEKpcezy386ynloittzhZOuIi4130_provenance.
• NP456358.RA6PgcWRfPINqeDc9fj4elgSNSlv6xB4sFFXAWEc7RFnQ130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456358.RA6PgcWRfPINqeDc9fj4elgSNSlv6xB4sFFXAWEc7RFnQ130_provenance.
• NP456360.RAxiNhkTKBWp5petuQYnJlNfwF1QuhHP1EsDekojEq5wI130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456360.RAxiNhkTKBWp5petuQYnJlNfwF1QuhHP1EsDekojEq5wI130_provenance.
• NP456364.RA6iHhAMvC1IvEskDF97wnKjgY-kBdNQnaSYSJDAzCwQ4130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456364.RA6iHhAMvC1IvEskDF97wnKjgY-kBdNQnaSYSJDAzCwQ4130_provenance.
• NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_provenance.
• NP456368.RA5Hwe4UslCz3okr3CaoDZq2nolP0FQsZLCxiejiS4Bo0130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456368.RA5Hwe4UslCz3okr3CaoDZq2nolP0FQsZLCxiejiS4Bo0130_provenance.